# Rusfertide

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/rusfertide
Canonical HTML page: https://getyourbrief.com/entity/rusfertide

## Timeline

- **2026-02-25**: Institutional Exit Revealed — 13F filings reveal a $170 million divestment by a major institutional fund.
- **2026-02-25**: Institutional Exit — SEC filings reveal a $170 million position liquidation by a major fund.
- **2026-01-20**: 120% Gain Milestone — PTGX stock reaches a 120% gain milestone from its 52-week low.
- **2025-11-01**: J&J Partnership Milestone — Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
- **2025-Q4**: 120% Rally — Stock price reaches a 12-month peak following sustained clinical momentum.
- **2025-06-15**: Phase 3 Data Release — Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
- **2025-Q1**: J&J Partnership Expansion — Johnson & Johnson expands the scope of the oral peptide collaboration.
- **2024-Q3**: Phase 2 Success — JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.

## Recent coverage (5 stories, network-wide)

### PTGX's 2 Shot-on-Goal Strategy: ICOTYDE Approved, Rusfertide Priority Review, $620M Cash
2026-06-14 01:25:38 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
Full story: https://getbiobrief.com/story/ptgx-2-shots-on-goal-icotyde-approved-rusfertide-priority-review

### How Protagonist’s $620M Cash Runway Through 2028 Supports 2 Peptide Drug Launches
2026-06-14 01:25:03 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

Protagonist Therapeutics' shift to a royalty-driven, capital-light model ensures sustained funding for two near-term peptide drug launches. With over $620 million in cash, the company is poised to deliver new treatment options while minimizing financial risk.
Full story: https://gethealthbrief.com/story/protagonist-therapeutics-620m-cash-runway-2-drug-launches-health

### Protagonist Therapeutics Surges 120% as Major Fund Discloses $170M Exit
2026-02-25 21:54:31 · Sector: startups · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
Full story: https://getstartupbrief.com/story/protagonist-therapeutics-120-percent-surge-170-million-exit

### Protagonist Stock Surges 120% as Major Fund Reveals $170 Million Exit
2026-02-25 21:49:49 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Full story: https://getfinancebrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit

### Protagonist Therapeutics Surges 120% as Major Fund Trims $170M Stake
2026-02-25 21:44:08 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Full story: https://getbiobrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.